Private Equity Lyon: Top Firms in 2026

Key Facts

• Between 15 and 25 active private equity and venture capital firms maintain offices in Lyon or direct investment mandates toward the Auvergne-Rhône-Alpes region.
• Fund sizes span from €10M seed vehicles to €568M buyout funds, with the Mérieux Participations 4 fund representing the largest confirmed close among Lyon-headquartered managers.
• ARCHIMED's MED I fund, a 2014-vintage healthcare buyout vehicle headquartered in Lyon, generated a 7.2x return and a 59% internal rate of return (IRR) over 11 years before full liquidation in November 2025.
• iXO Private Equity has deployed €750M across 300 transactions over 15 years, serving small and mid-sized enterprises (SMEs) across the Auvergne-Rhône-Alpes corridor.
• Healthcare is the dominant sector, with ARCHIMED and Mérieux Equity Partners both exclusively focused on healthcare and nutrition investment from their Lyon bases.
• Average deal sizes range from €2M to €80M depending on strategy, with early-stage innovation vehicles writing €3M to €15M checks and buyout platforms targeting €20M to €80M.
• Active fundraising continues into 2025: Mérieux Innovation 2 reached a €300M first close in February 2025, signaling sustained limited partner (LP) demand for Lyon-based healthcare managers.

Private Equity in Lyon, France: Market Overview

Lyon occupies a distinctive position in French private equity. As the capital of the Auvergne-Rhône-Alpes region and France's second-largest metropolitan economy, the city has cultivated a PE ecosystem defined by deep sector concentration rather than broad generalism. Two forces shape this concentration: the Mérieux family's century-long life sciences heritage, which seeded both ARCHIMED and Mérieux Equity Partners, and a robust regional industrial base that sustains a steady flow of mid-market SME transactions.

The Lyon private equity market spans the full capital stack from pre-seed accelerators to €500M-plus buyout funds. Firms like Axeleo Capital and HUB612 serve the earliest stage, while Mérieux Equity Partners operates dual Innovation and Buyout platforms with mandates stretching from seed to profitable growth companies. This diversity means the city supports founders at every stage of development, not only the established businesses that typically attract buyout capital.

Regulation and association membership provide the structural backbone of the local market. The Autorité des Marchés Financiers (AMF) governs French PE fund managers handling third-party capital, and France Invest serves as the national industry association. Lyon Place Financière et Tertiaire, the regional financial sector body, counts ARCHIMED among its members. Compared to Paris, Lyon's market is more concentrated in healthcare, runs on smaller average ticket sizes, and draws a higher share of its deal flow from regional Auvergne-Rhône-Alpes businesses rather than national or pan-European sourcing.

Firm Comparison at a Glance

PE investors and buyout firms operating in the Lyon ecosystem range from globally focused healthcare specialists to generalist regional players, making a side-by-side comparison essential for anyone evaluating capital partners in the market.

Healthcare PE commands the most disclosed fund capital at the firm level, while energy transition infrastructure dominates in absolute AUM terms through Omnes Capital's Capenergie platform.

Top Picks by Investment Strategy

Healthcare Buyout Leader: ARCHIMED. The only globally focused healthcare PE firm headquartered in Lyon, ARCHIMED delivered a 7.2x return on its MED I fund over 11 years, a performance described at the time of liquidation as the best of any 2014-vintage buyout fund globally. Its investment scope covers eight healthcare sub-verticals including MedTech, Biopharma, Diagnostics, and Healthcare IT.

Healthcare Innovation Platform: Mérieux Equity Partners. The dual-platform structure, with a Buyout vehicle (MP4 closed at €568M with 11 investments) and an Innovation fund (MI2 at €300M first close and currently deploying), gives Mérieux Equity Partners unmatched coverage from seed-stage medical solutions to profitable growth companies seeking majority or minority capital.

Strongest Regional Mid-Market Track Record: iXO Private Equity. With €1B in assets under management, 300 completed transactions, and €750M deployed over 15 years, iXO PE offers the deepest regional deal history among Lyon-area generalist investors, writing checks from €2M to €30M for Auvergne-Rhône-Alpes SMEs.

Energy Transition and Deeptech Scale: Omnes Capital. Paris-headquartered but active across Europe, Omnes directs €4.4B through its Capenergie renewable energy platform and manages a dedicated €650M deeptech fund, making it the only firm in this cohort with institutional-scale capital available for infrastructure and hard science investing.

Top Early-Stage B2B Digital: Axeleo Capital. Backed by a community of operating entrepreneurs rather than a single family or corporate sponsor, Axeleo Capital has built a differentiated seed and early-stage model for French B2B software businesses since its 2017 founding.

Family Office VC: Evolem Start. The investment arm of the Evolem family office, which manages $800M in total assets, Evolem Start deploys patient seed and Series A capital across sectors throughout France, with no sector restriction constraining its deal flow.

Generalist Regional Coverage: Siparex Group. With a France Invest-listed presence and investment activity across more than 30 sectors from seed through Series B, Siparex offers the broadest sector mandate among regional French PE participants.

Top Lyon PE and VC Firms in Detail

ARCHIMED

The defining proof point for ARCHIMED's investment thesis is MED I: a 2014-vintage healthcare buyout fund that generated 7.2 times invested capital and a 59% annual IRR over 11 years, achieving full liquidation in November 2025 with Citieffe as its final portfolio exit. No other 2014-vintage buyout fund matched this return profile. The firm's scope spans eight sub-verticals: Animal and Environmental Health, Biopharma, Consumer Health, Diagnostics, Healthcare IT, Life Science Tools, MedTech, and Pharma Services. Cross-border deal activity includes the 2025 acquisition of ARK, a California-based specialty business previously held by South Korean listed company Soulbrain Holdings, and the carve-out of SuanNutra from Suanfarma into a standalone nutraceutical ingredients leader. Healthcare-focused institutional LPs seeking a Europe-based general partner (GP) with a verified global exit track record will find ARCHIMED the most relevant benchmark in this market.

Mérieux Equity Partners

The most structurally distinctive firm in the Lyon ecosystem, Mérieux Equity Partners runs two separate investment platforms under one roof: an Innovation vehicle targeting seed through Series B medical solutions with minority stakes at €3M to €15M per company, and a Buyout vehicle targeting profitable growth businesses at €20M to €80M with majority or minority structures. Mérieux Participations 4 (MP4) closed at €568M in September 2023 and has already completed 11 investments. Mérieux Innovation 2 (MI2), the current innovation vehicle, reached a €300M first close in February 2025 and has made its first investment. AMF registration and a Paris satellite office complement the primary Lyon headquarters. Founders building Series A medical solutions and LPs seeking staged exposure to both early-stage and buyout healthcare strategies within a single GP relationship benefit most from this dual-platform structure.

iXO Private Equity

Regional deal depth is iXO Private Equity's defining advantage. The firm has completed 300 transactions and deployed €750M over 15 years while maintaining a current portfolio of 70 companies, all within the Grand Sud France and Auvergne-Rhône-Alpes corridor. Its Lyon office is one of four regional presences (alongside Toulouse, Bordeaux, and Marseille), reflecting a decentralized model built for sourcing SME transactions outside the Paris market. Ticket sizes run from €2M to €30M, with both minority and majority structures available depending on founder preference. The firm's 2025 exits illustrate portfolio breadth: FINMED Group, a medical technology business, was sold to pan-European healthcare group Asker Healthcare, while GA Smart Building completed a capital restructuring supporting low-carbon construction growth. Business owners in the Auvergne-Rhône-Alpes region seeking a growth equity or buyout partner with genuine local presence and 300 completed transactions as evidence of execution capability should consider iXO Private Equity their starting point.

Omnes Capital

Omnes Capital operates at a scale that sets it apart from every other firm in this comparison. Its €6.7B in managed capital spans four distinct strategies: €4.4B in renewable energy infrastructure through the Capenergie platform, €362M in sustainable cities through Construction Energie Plus, €650M in deeptech, and €780M raised since 2008 for co-investment positions in sustainable PE deals across Europe and North America. The firm is Paris-headquartered with offices in Brussels, Zurich, and Munich, which means it serves the Lyon market as part of a broader European platform rather than as a regionally dedicated manager. Its co-investment vehicle is notable: LPs seeking minority positions in high-quality European PE deals alongside established GPs can access this through Omnes's dedicated program. Among Lyon-area managers, no comparable platform exists for institutional investors building energy transition or hard science exposure.

Axeleo Capital

Axeleo Capital brings a structurally different model to the Lyon early-stage ecosystem. Backed not by a single family or corporate anchor but by a community of operating entrepreneurs, the firm combines seed and early-stage capital with an operational network that provides portfolio companies direct access to B2B go-to-market expertise from founders who have built and scaled French digital businesses. Its investment focus is exclusively B2B digital startups, with deal flow concentrated in French software and technology companies. The 2017 founding date means Axeleo is building its track record across the current fund cycle, making it most relevant to founders who value operational peer networks and early-stage conviction over the brand recognition of established managers. Software founders seeking French-language operational support alongside institutional capital will find the entrepreneur-community model hard to replicate elsewhere in Lyon.

Evolem Start

The Evolem family office, founded and led by entrepreneur Bruno Rousset, manages $800M in total assets. Evolem Start, the investment vehicle within the family office, deploys seed and Series A capital across all sectors within France with no geographic restriction. The family office model means Evolem operates without fund lifecycle pressure, enabling patient capital deployment on timelines that institutional PE structures cannot always match. Sector agnosticism is genuine rather than aspirational: the absence of a thesis constraint allows Evolem to evaluate consumer, technology, and industrial opportunities on equal terms. For founders at the pre-Series A stage who have exhausted friends-and-family rounds but are not yet ready for a venture firm with sector mandates, Evolem Start offers a flexible capital source with a proven backing institution behind it.

Hi Inov - Dentressangle

The Dentressangle family name, associated with building one of France's largest logistics businesses before its sale to XPO Logistics, gives Hi Inov a credibility anchor that distinguishes it from purely financial sponsors. The firm focuses exclusively on early-stage B2B digital startups and shares Axeleo Capital's emphasis on operational value creation alongside financial capital. Hi Inov's 2013 founding predates Axeleo by four years, giving it a longer track record in the Lyon B2B digital segment. For founders building enterprise software or digital services businesses who want backing from investors with direct operational experience scaling a French company to European scale, Hi Inov's Dentressangle heritage represents a specific and verifiable proof point of that capability.

Siparex Group

Siparex brings the broadest sector mandate of any firm in this cohort, covering agriculture, business services, and more than 29 additional sectors with investment activity spanning seed through Series B. Its France Invest listing confirms regulatory standing and institutional credibility within the French PE association framework. The firm's generalist approach contrasts sharply with ARCHIMED's and Mérieux's sector exclusivity, making Siparex relevant for businesses in sectors underserved by Lyon's healthcare and deeptech specialists. Companies in manufacturing, agriculture, or business services that do not fit the mandates of the city's sector-focused GPs have a viable regional alternative in Siparex without relocating their investor search to Paris.

Investment Trends and Capital Flows

Healthcare Industry Consolidation

ARCHIMED and Mérieux Equity Partners collectively represent Lyon's two most active healthcare PE engines, with both fund managers deploying fresh capital into European healthcare consolidation. ARCHIMED's 2025 deal activity, including the California-based ARK acquisition and the SuanNutra carve-out from Suanfarma, demonstrates appetite for cross-border and corporate separation transactions that extend well beyond the French market. The 7.2x MED I return has already generated LP demand for successor vehicles, sustaining the capital base needed for continued deal flow in this segment.

Energy Transition and Renewable Infrastructure

Omnes Capital's Capenergie platform directs €4.4B into renewable energy projects across Europe, with a further €362M through the Construction Energie Plus fund targeting sustainable urban infrastructure. ESG mandates from pension funds and endowments are accelerating capital allocation into this strategy. Omnes's co-investment program provides access for LPs who want exposure to the strongest individual deals rather than a full fund commitment, and the scale of this platform has no comparable equivalent among Lyon-area managers.

Deeptech and Hard Science Startups

Omnes Capital's dedicated €650M deeptech fund anchors the institutional layer of Lyon's hard science investing ecosystem. Lyon's research infrastructure, including affiliations with CNRS and INSERM, generates a pipeline of university spinouts and scientific ventures that feed both the Omnes deeptech fund and earlier-stage investors. Axeleo Capital bridges the gap between pre-seed technical startups and the later-stage deeptech mandates that require larger fund sizes and longer hold periods.

B2B Digital SaaS and Early-Stage VC

Axeleo Capital and Hi Inov together serve the French B2B software startup ecosystem from Lyon with complementary models: Axeleo's entrepreneur-network model emphasizes peer operational support, while Hi Inov draws on the Dentressangle family's corporate growth experience. Both firms target pre-Series B companies, creating a structured pathway for B2B digital businesses from seed through Series A and into later-stage growth financing. The expanding French SaaS ecosystem, with Paris as the primary cluster and Lyon as a secondary node, continues to generate investment opportunities for both managers.

ESG and Impact-Driven Mandates

iXO Private Equity publishes explicit RSE (Responsabilité Sociétale des Entreprises) commitments in its annual reporting, positioning ESG governance as a core element of its SME partnership model rather than a marketing overlay. Omnes Capital builds its entire firm identity around a "resilient planet" mission, making energy transition and sustainability outcomes inseparable from its investment thesis. ARCHIMED frames healthcare investment as societal impact, an argument that resonates with ESG-conscious institutional LPs who require demonstrable non-financial return alongside financial performance. This alignment between GP mission and LP demand is strengthening across the Lyon ecosystem and is likely to accelerate as French regulatory frameworks impose stricter ESG disclosure requirements on AMF-registered managers.

How to Evaluate PE Investors in This Market

Stage fit is the first and most consequential filter when evaluating Lyon-based PE investors. A profitable healthcare company with €5M in EBITDA belongs in a conversation with Mérieux Buyout or iXO PE, not Mérieux Innovation or Axeleo Capital. Mapping your company's revenue, profitability, and growth trajectory to the firm's stated ticket size and ownership preference before making contact eliminates the most common mismatches.

AMF registration provides the baseline regulatory assurance for French asset managers handling third-party capital. Mérieux Equity Partners states its AMF-registered status explicitly, and this transparency should be the expected standard. The France Invest directory lists verified member firms, including AMDG PE, and serves as a practical starting point for checking a firm's standing before engaging. Any Lyon-based firm managing LP capital without clear AMF registration warrants additional due diligence scrutiny.

Fund vintage and deployment status determine whether a firm can actually invest. ARCHIMED MED I was fully liquidated in November 2025, so a successor fund is the relevant vehicle for new investments. MP4 closed in September 2023 with 11 investments already made, meaning capacity may be limited depending on fund size. MI2 opened in February 2025 with a €300M first close and one investment completed, making it the most active Mérieux vehicle for new opportunities. Understanding whether a fund is in early deployment, nearly fully invested, or in exit mode is essential before committing time to a process.

Track record assessment should go beyond headline returns. ARCHIMED MED I's 7.2x multiple on invested capital and 59% annual IRR are exceptional benchmarks. iXO PE's 300 transactions over 15 years and €750M deployed provides a different but equally credible proof point of execution consistency. LPs evaluating multiple offerings should request fund-level performance data, including carried interest waterfall mechanics and hurdle rate structures, to ensure alignment between the GP's incentive structure and their own return expectations.

Majority versus minority stake preference is a negotiating variable at some firms but a fixed constraint at others. Mérieux Innovation mandates minority positions across all innovation-stage investments. iXO PE and Mérieux Buyout both accommodate majority and minority structures depending on the transaction. Knowing your own preference before entering discussions allows for a faster and more honest qualification conversation.

Which Firm Fits Your Needs?

Founders building healthcare or medtech businesses at the seed to Series B stage have two strong options in the Lyon ecosystem. Mérieux Innovation 2, currently in active deployment after a €300M first close, targets minority investments of €3M to €15M per company and explicitly supports innovative medical solutions. For founders outside healthcare working on B2B software or digital services, Axeleo Capital offers seed-stage capital alongside a community of operating entrepreneurs who provide go-to-market support that financial sponsors alone cannot replicate.

Mid-market business owners in the Auvergne-Rhône-Alpes region with profitable companies seeking growth capital or a partial or full exit have two distinct paths. iXO Private Equity, with a Lyon office among its four regional locations and 300 completed transactions as proof of regional commitment, serves businesses requiring €2M to €30M with minority or majority structures. Mérieux Buyout targets a higher ticket range of €20M to €80M for companies with stronger profitability profiles, and its focus on healthcare and nutrition means sector fit is essential before approaching the firm.

LPs allocating to alternatives face a clear bifurcation in this market. Healthcare PE exposure with a verified exit benchmark is most directly available through ARCHIMED, which is raising a successor vehicle following MED I's liquidation, and through Mérieux Equity Partners' dual platforms. LPs seeking energy transition or infrastructure exposure at institutional scale should look to Omnes Capital, whose €6.7B AUM and co-investment program provide access to the most developed renewable energy and deeptech platform in the regional cohort. Advisors structuring portfolios for clients with French regional mandates should note that iXO PE's Lyon office and 70-company portfolio make it the most operationally accessible mid-market generalist in the Auvergne-Rhône-Alpes region.

Methodology

This guide to private equity in Lyon was compiled using data from the France Invest member directory, AMF registration records, firm websites, investor database listings, and industry publication profiles. Firms were included based on an active Lyon office presence, an explicit Auvergne-Rhône-Alpes geographic investment mandate, or a significant historical role in the regional ecosystem. AUM figures reflect firm-disclosed data and are listed as undisclosed where firms have not published figures publicly. Fund performance data, including ARCHIMED MED I's 7.2x return, is sourced from firm announcements. Data reflects information available as of early 2026, with active fundraising status based on the most recent publicly available fund information at time of publication.